We are Sorry, This Page doesn't Exist
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 12) read more.....»»
Applied Genetic Technologies: Biogen"s Deal Termination Was Premature
Applied Genetic Technologies: Biogen"s Deal Termination Was Premature.....»»
Tackling deadly newborn disease, BridgeBio affiliate wins FDA drug approval
The BridgeBio model is designed to move drugs tackling rare diseases with a well-defined genetic basis quickly and efficiently to approval......»»
Former gene-silencing rivals bury the hatchet with new partnership
Former foes Alnylam Pharmaceuticals and Dicerna Pharmaceuticals Inc. are joining forces, with plans to work together on multiple gene-silencing drugs. Alnylam (Nasdaq: ALNY) and Dicerna (Nasdaq: DRNA) say they'll work to treat a genetic disease called.....»»
Applied Materials, Lam Research among 10 stocks getting downgrades at B. Riley
B. Riley analyst Craig Ellis downgraded 10 chip stocks to neutral from buy on Thursday, writing that he "underestimated potential for a risk" from outbreak of COVID-19, the disease brought on by the novel coronavirus. Among the na.....»»
The Zacks Analyst Blog Highlights: Apple, Applied Materials, Synopsys, Copart and State Street
Zacks.....»»
Biogen signs neuro disease drug deal with Cambridge startup
A young biotech startup hoping to map out the actions of cells throughout the body has signed its second major drug development partner with biotech giant Biogen......»»
The Zacks Analyst Blog Highlights: QUALCOMM, Ichor, Applied Materials, KLA-Tencor and MACOM
Zacks.....»»
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
Zacks.....»»
Top Analyst Upgrades and Downgrades: Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap, Wayfair and More
Stocks traded higher to all-time highs on Thursday on news that a China trade deal was very close, seemingly without any cares about impeachment, and the indexes were indicated up another 0.25% or so........»»
Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug
Shares of Biogen rose 4.5% in afternoon trading in response to new data that indicates its recently resurrected experimental Alzheimer’s disease treatment can reduce cognitive decline......»»
Top Analyst Upgrades and Downgrades: Albermarle, Amgen, Applied Materials, Biogen, CRISPR, CrowdStrike, CSX, Kroger, Slack, Teva, Xerox and More
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox......»»
Applied Genetic announces Stargardt disease as preclinical ophthalmology program
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Gilead strikes deal with Nurix Therapeutics to tackle disease-causing proteins
Gilead Sciences Inc. is partnering with Nurix Therapeutics, a biotech working on drugs to destroy disease-causing.....»»
Biogen, Amgen, Novartis Still Banking on Amyloid Therapies for Alzheimer’s
Although amyloid drugs to treat Alzheimer's disease have disappointed in clinical tests, some researchers -and pharmaceutical companies- still think they can be effectiveRelated Stocks: BIIB, AMGN, NVS, LLY, ABBV, VTVT,.....»»
Biogen shares leap as Alzheimer"s drug shows potential to slow disease
Biogen gained billions of dollars in market value on Friday after announcing promising results from a trial of one of its experimental Alzheimer’s disease drugs, marking a rare dose of good news in the daunting field. Cambridge-based Biogen (Nasda.....»»